5300192025-10-012025-12-315300192025-12-315300192025-04-012025-12-315300192025-10-012025-12-31in-capmkt:OtherExpenses1Member5300192025-04-012025-12-31in-capmkt:OtherExpenses1Member5300192025-10-012025-12-31in-capmkt:ReportableSegments1Member5300192025-10-012025-12-31in-capmkt:ReportableSegments2Member5300192025-10-012025-12-31in-capmkt:ReportableSegments3Member5300192025-10-012025-12-31in-capmkt:ReportableSegments4Member5300192025-10-012025-12-31in-capmkt:ReportableSegments5Member5300192025-10-012025-12-31in-capmkt:ReportableSegments6Member5300192025-10-012025-12-31in-capmkt:ReportableSegments7Member5300192025-04-012025-12-31in-capmkt:ReportableSegments1Member5300192025-04-012025-12-31in-capmkt:ReportableSegments2Member5300192025-04-012025-12-31in-capmkt:ReportableSegments3Member5300192025-04-012025-12-31in-capmkt:ReportableSegments4Member5300192025-04-012025-12-31in-capmkt:ReportableSegments5Member5300192025-04-012025-12-31in-capmkt:ReportableSegments6Member5300192025-04-012025-12-31in-capmkt:ReportableSegments7Member5300192025-10-012025-12-31in-capmkt:ReportableSegments1Member5300192025-10-012025-12-31in-capmkt:ReportableSegments2Member5300192025-10-012025-12-31in-capmkt:ReportableSegments3Member5300192025-10-012025-12-31in-capmkt:ReportableSegments4Member5300192025-10-012025-12-31in-capmkt:ReportableSegments5Member5300192025-10-012025-12-31in-capmkt:ReportableSegments6Member5300192025-10-012025-12-31in-capmkt:ReportableSegments7Member5300192025-04-012025-12-31in-capmkt:ReportableSegments1Member5300192025-04-012025-12-31in-capmkt:ReportableSegments2Member5300192025-04-012025-12-31in-capmkt:ReportableSegments3Member5300192025-04-012025-12-31in-capmkt:ReportableSegments4Member5300192025-04-012025-12-31in-capmkt:ReportableSegments5Member5300192025-04-012025-12-31in-capmkt:ReportableSegments6Member5300192025-04-012025-12-31in-capmkt:ReportableSegments7Member5300192025-10-012025-12-31in-capmkt:ReportableSegments1Member5300192025-12-31in-capmkt:ReportableSegments1Member5300192025-10-012025-12-31in-capmkt:ReportableSegments2Member5300192025-12-31in-capmkt:ReportableSegments2Member5300192025-10-012025-12-31in-capmkt:ReportableSegments3Member5300192025-12-31in-capmkt:ReportableSegments3Member5300192025-10-012025-12-31in-capmkt:ReportableSegments4Member5300192025-12-31in-capmkt:ReportableSegments4Member5300192025-10-012025-12-31in-capmkt:ReportableSegments5Member5300192025-12-31in-capmkt:ReportableSegments5Member5300192025-10-012025-12-31in-capmkt:ReportableSegments6Member5300192025-12-31in-capmkt:ReportableSegments6Member5300192025-10-012025-12-31in-capmkt:ReportableSegments7Member5300192025-12-31in-capmkt:ReportableSegments7Member5300192025-10-012025-12-31in-capmkt:ReportableSegments1Member5300192025-12-31in-capmkt:ReportableSegments1Member5300192025-10-012025-12-31in-capmkt:ReportableSegments2Member5300192025-12-31in-capmkt:ReportableSegments2Member5300192025-10-012025-12-31in-capmkt:ReportableSegments3Member5300192025-12-31in-capmkt:ReportableSegments3Member5300192025-10-012025-12-31in-capmkt:ReportableSegments4Member5300192025-12-31in-capmkt:ReportableSegments4Member5300192025-10-012025-12-31in-capmkt:ReportableSegments5Member5300192025-12-31in-capmkt:ReportableSegments5Member5300192025-10-012025-12-31in-capmkt:ReportableSegments6Member5300192025-12-31in-capmkt:ReportableSegments6Member5300192025-10-012025-12-31in-capmkt:ReportableSegments7Member5300192025-12-31in-capmkt:ReportableSegments7Member5300192025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15300192025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15300192025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15300192025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares530019JUBLPHARMANOTLISTEDINE700A01033JUBILANT PHARMOVA LIMITEDMain BoardEquity2025-04-012026-03-312026-02-062026-01-22INRMillionsQuarterlyThird quarterMulti segment2026-02-0610:30:002026-02-0612:35:00Not applicable2025-10-012025-12-31UnauditedConsolidated21225000000205000000214300000005921000000820000000422000000706400000056100000012070000004103000000200980000001332000000-3970000009350000002160000001600000003760000000559000000000-10000005580000006240000001182000000559000000-10000001181000000100000015800000013.523.52003.523.522025-04-012025-12-31UnauditedConsolidated5989600000042300000060319000000167750000002286000000249000000193370000001553000000323600000012044000000554800000004839000000-4550000004384000000952000000647000000159900000002785000000000-30000002782000000263900000054210000002791000000-90000005435000000-14000000158000000117.617.560017.617.56Other Expenses4103000000Other Expenses12044000000Radiopharma9344000000Allergy Immunotherapy1927000000Contract Development and Manufacturing Organisation - Sterile Injectables4620000000Contract Research, Development and Manufacturing Organisation3062000000Generics2261000000Proprietary Novel Drugs0Unallocable corporate149000000Radiopharma27001000000Allergy Immunotherapy5781000000Contract Development and Manufacturing Organisation - Sterile Injectables12661000000Contract Research, Development and Manufacturing Organisation9301000000Generics5591000000Proprietary Novel Drugs0Unallocable corporate43700000021363000000607720000001380000008760000002122500000059896000000Radiopharma880000000Allergy Immunotherapy457000000Contract Development and Manufacturing Organisation - Sterile Injectables363000000Contract Research, Development and Manufacturing Organisation318000000Generics109000000Proprietary Novel Drugs-29000000Unallocable corporate0Radiopharma2821000000Allergy Immunotherapy1819000000Contract Development and Manufacturing Organisation - Sterile Injectables1504000000Contract Research, Development and Manufacturing Organisation878000000Generics102000000Proprietary Novel Drugs-120000000Unallocable corporate020980000007004000000561000000155300000060300000010700000009340000004381000000Radiopharma31651000000Allergy Immunotherapy6076000000Contract Development and Manufacturing Organisation - Sterile Injectables55169000000Contract Research, Development and Manufacturing Organisation18369000000Generics12891000000Proprietary Novel Drugs3044000000Unallocable corporate012720000000017446000000144646000000Radiopharma9971000000Allergy Immunotherapy958000000Contract Development and Manufacturing Organisation - Sterile Injectables25690000000Contract Research, Development and Manufacturing Organisation4423000000Generics2676000000Proprietary Novel Drugs76000000Unallocable corporate0437940000003393400000077728000000Items that will not be reclassified to profit or loss40000004000000Items that will not be reclassified to profit or loss-13000000-130000001000000-5000000Items that will be reclassified to profit or loss621000000621000000Items that will be reclassified to profit or loss26470000002647000000006240000002639000000